Insurance
nib offers genetic testing
Rob Hennin
Thursday 21st of March 2019
In a release, the insurer said women with ovarian cancer were able to access testing in the private health system to work out the best course of treatment.
Patients with a BRCA mutation gene are likely to benefit from the addition of a treatment called PARP inhibitors.
Chief executive Rob Hennin said genomic profiling played an increasing role in the treatment and management of cancer.
“We want to ensure our members have the best possible treatment to help them fight this insidious disease,” Hennin said.
Want to read the full article?
Click the button below to subscribe and will have free unlimited access for a limited time to full article and all other articles on the site.
You will also be able to comment on articles on Good Returns.
Latest News
3 min read
3 min read
2 min read
Latest Comments
The Devil’s Advocate may be an adviser’s best friend
Ha, good one Philip!
2 days ago Steve Wright
SIFA puts quality ahead of growth
Great to hear the SIFA culture lives on!
5 days ago Ross Sheerin